JP2015533170A - 少なくとも一種のヒドロトロープ及び少なくとも一種の活性化合物を含む化粧品組成物 - Google Patents
少なくとも一種のヒドロトロープ及び少なくとも一種の活性化合物を含む化粧品組成物 Download PDFInfo
- Publication number
- JP2015533170A JP2015533170A JP2015536914A JP2015536914A JP2015533170A JP 2015533170 A JP2015533170 A JP 2015533170A JP 2015536914 A JP2015536914 A JP 2015536914A JP 2015536914 A JP2015536914 A JP 2015536914A JP 2015533170 A JP2015533170 A JP 2015533170A
- Authority
- JP
- Japan
- Prior art keywords
- hydrotrope
- adenosine
- composition
- active compound
- caffeine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 176
- 239000003752 hydrotrope Substances 0.000 title claims abstract description 171
- QUCDWLYKDRVKMI-UHFFFAOYSA-M sodium;3,4-dimethylbenzenesulfonate Chemical compound [Na+].CC1=CC=C(S([O-])(=O)=O)C=C1C QUCDWLYKDRVKMI-UHFFFAOYSA-M 0.000 title claims abstract description 126
- 150000001875 compounds Chemical class 0.000 title claims abstract description 118
- 239000002537 cosmetic Substances 0.000 title claims abstract description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 87
- 238000000034 method Methods 0.000 claims abstract description 45
- 230000035515 penetration Effects 0.000 claims abstract description 33
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 141
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 90
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 70
- 229960005305 adenosine Drugs 0.000 claims description 70
- 150000002989 phenols Chemical class 0.000 claims description 59
- 150000003838 adenosines Chemical class 0.000 claims description 54
- 235000013824 polyphenols Nutrition 0.000 claims description 49
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 45
- 229960001948 caffeine Drugs 0.000 claims description 45
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 45
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 44
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 36
- 229960003966 nicotinamide Drugs 0.000 claims description 20
- 235000005152 nicotinamide Nutrition 0.000 claims description 20
- 239000011570 nicotinamide Substances 0.000 claims description 20
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 claims description 18
- 229960004025 sodium salicylate Drugs 0.000 claims description 18
- CRPCXAMJWCDHFM-UHFFFAOYSA-M sodium;5-oxopyrrolidine-2-carboxylate Chemical compound [Na+].[O-]C(=O)C1CCC(=O)N1 CRPCXAMJWCDHFM-UHFFFAOYSA-M 0.000 claims description 16
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 14
- 229940126062 Compound A Drugs 0.000 claims 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 1
- 230000000149 penetrating effect Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 8
- 239000012071 phase Substances 0.000 description 46
- 210000003491 skin Anatomy 0.000 description 36
- 239000000243 solution Substances 0.000 description 31
- 238000009472 formulation Methods 0.000 description 28
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 26
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 19
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 19
- 229960003321 baicalin Drugs 0.000 description 19
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 19
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 238000003756 stirring Methods 0.000 description 17
- 150000002632 lipids Chemical class 0.000 description 16
- 238000002156 mixing Methods 0.000 description 16
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 13
- 239000008103 glucose Substances 0.000 description 13
- 239000003963 antioxidant agent Substances 0.000 description 12
- 235000006708 antioxidants Nutrition 0.000 description 12
- -1 phenolic compounds Free radical Chemical class 0.000 description 11
- 239000000839 emulsion Substances 0.000 description 10
- 229930003935 flavonoid Natural products 0.000 description 10
- 235000017173 flavonoids Nutrition 0.000 description 10
- 239000003960 organic solvent Substances 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 9
- 229930003268 Vitamin C Natural products 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000006071 cream Substances 0.000 description 9
- 150000002215 flavonoids Chemical class 0.000 description 9
- 235000019154 vitamin C Nutrition 0.000 description 9
- 239000011718 vitamin C Substances 0.000 description 9
- 238000010438 heat treatment Methods 0.000 description 8
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 7
- 239000006210 lotion Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000000699 topical effect Effects 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000032683 aging Effects 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 6
- 239000003623 enhancer Substances 0.000 description 6
- 230000002633 protecting effect Effects 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 235000014366 other mixer Nutrition 0.000 description 5
- 230000007928 solubilization Effects 0.000 description 5
- 238000005063 solubilization Methods 0.000 description 5
- 230000037303 wrinkles Effects 0.000 description 5
- 239000000232 Lipid Bilayer Substances 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 230000003165 hydrotropic effect Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000037380 skin damage Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- HXKKHQJGJAFBHI-UHFFFAOYSA-N 1-aminopropan-2-ol Chemical compound CC(O)CN HXKKHQJGJAFBHI-UHFFFAOYSA-N 0.000 description 3
- 108050000203 Adenosine receptors Proteins 0.000 description 3
- 102000009346 Adenosine receptors Human genes 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 150000002433 hydrophilic molecules Chemical class 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 229940102253 isopropanolamine Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 230000002040 relaxant effect Effects 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000037317 transdermal delivery Effects 0.000 description 3
- XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 description 2
- RIRGCFBBHQEQQH-UVCRECLJSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-(1-phenylpropan-2-ylamino)purin-9-yl]oxolane-3,4-diol Chemical compound N=1C=NC=2N([C@H]3[C@@H]([C@H](O)[C@@H](CO)O3)O)C=NC=2C=1NC(C)CC1=CC=CC=C1 RIRGCFBBHQEQQH-UVCRECLJSA-N 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 2
- WSRCOZWDQPJAQT-UHFFFAOYSA-N 18-methylicosanoic acid Chemical compound CCC(C)CCCCCCCCCCCCCCCCC(O)=O WSRCOZWDQPJAQT-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- CLAHOZSYMRNIPY-UHFFFAOYSA-N 2-hydroxyethylurea Chemical compound NC(=O)NCCO CLAHOZSYMRNIPY-UHFFFAOYSA-N 0.000 description 2
- IOSAAWHGJUZBOG-UHFFFAOYSA-N 3-(6-amino-9h-purin-9-yl)nonan-2-ol Chemical compound N1=CN=C2N(C(C(C)O)CCCCCC)C=NC2=C1N IOSAAWHGJUZBOG-UHFFFAOYSA-N 0.000 description 2
- OLXZPDWKRNYJJZ-UHFFFAOYSA-N 5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol Chemical compound C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(CO)O1 OLXZPDWKRNYJJZ-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010015776 Glucose oxidase Proteins 0.000 description 2
- 239000004366 Glucose oxidase Substances 0.000 description 2
- JUUBCHWRXWPFFH-UHFFFAOYSA-N Hydroxytyrosol Chemical compound OCCC1=CC=C(O)C(O)=C1 JUUBCHWRXWPFFH-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000002082 coherent anti-Stokes Raman spectroscopy Methods 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 2
- 235000001785 ferulic acid Nutrition 0.000 description 2
- 229940114124 ferulic acid Drugs 0.000 description 2
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 229940116332 glucose oxidase Drugs 0.000 description 2
- 235000019420 glucose oxidase Nutrition 0.000 description 2
- 229940031575 hydroxyethyl urea Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 2
- 229940045136 urea Drugs 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- HGXBRUKMWQGOIE-AFHBHXEDSA-N (+)-pinoresinol Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@@H]3[C@@H]([C@H](OC3)C=3C=C(OC)C(O)=CC=3)CO2)=C1 HGXBRUKMWQGOIE-AFHBHXEDSA-N 0.000 description 1
- BIXYYZIIJIXVFW-UUOKFMHZSA-N (2R,3R,4S,5R)-2-(6-amino-2-chloro-9-purinyl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O BIXYYZIIJIXVFW-UUOKFMHZSA-N 0.000 description 1
- KQCFQSMHNZFZCQ-MCDZGGTQSA-N (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol N-ethylformamide Chemical compound CCNC=O.C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O KQCFQSMHNZFZCQ-MCDZGGTQSA-N 0.000 description 1
- QVUUUSJUORLECR-XNIJJKJLSA-N (2R,3R,4S,5R)-2-(6-anilino-9-purinyl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NC=3C=CC=CC=3)=C2N=C1 QVUUUSJUORLECR-XNIJJKJLSA-N 0.000 description 1
- QHFLZHVITNUFMV-KQYNXXCUSA-N (2r,3r,4s,5r)-2-(1-hydroxy-6-iminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CN(O)C2=N)=C2N=C1 QHFLZHVITNUFMV-KQYNXXCUSA-N 0.000 description 1
- CHMUHOFITZIING-XNIJJKJLSA-N (2r,3r,4s,5r)-2-(6-aminopurin-9-yl)-2-cyclohexyl-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@]1(C2CCCCC2)O[C@H](CO)[C@@H](O)[C@H]1O CHMUHOFITZIING-XNIJJKJLSA-N 0.000 description 1
- XHRJGHCQQPETRH-KQYNXXCUSA-N (2r,3r,4s,5r)-2-(6-chloropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(Cl)=C2N=C1 XHRJGHCQQPETRH-KQYNXXCUSA-N 0.000 description 1
- XSMYYYQVWPZWIZ-IDTAVKCVSA-N (2r,3r,4s,5r)-2-[2-chloro-6-(cyclopentylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC(Cl)=NC(NC3CCCC3)=C2N=C1 XSMYYYQVWPZWIZ-IDTAVKCVSA-N 0.000 description 1
- BUHVIAUBTBOHAG-FOYDDCNASA-N (2r,3r,4s,5r)-2-[6-[[2-(3,5-dimethoxyphenyl)-2-(2-methylphenyl)ethyl]amino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound COC1=CC(OC)=CC(C(CNC=2C=3N=CN(C=3N=CN=2)[C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)C=2C(=CC=CC=2)C)=C1 BUHVIAUBTBOHAG-FOYDDCNASA-N 0.000 description 1
- UHJRJLPSYJUCPF-SDBHATRESA-N (2r,3r,4s,5r)-2-[6-amino-2-(cyclohexylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound N=1C=2N([C@H]3[C@@H]([C@H](O)[C@@H](CO)O3)O)C=NC=2C(N)=NC=1NC1CCCCC1 UHJRJLPSYJUCPF-SDBHATRESA-N 0.000 description 1
- LGZYEDZSPHLISU-SCFUHWHPSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-(2-phenylethylamino)purin-9-yl]oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NCCC=3C=CC=CC=3)=C2N=C1 LGZYEDZSPHLISU-SCFUHWHPSA-N 0.000 description 1
- OOEMZCZWZXHBKW-SCFUHWHPSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-[(2-methylphenyl)methylamino]purin-9-yl]oxolane-3,4-diol Chemical compound CC1=CC=CC=C1CNC1=NC=NC2=C1N=CN2[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 OOEMZCZWZXHBKW-SCFUHWHPSA-N 0.000 description 1
- PLYRYAHDNXANEG-QMWPFBOUSA-N (2s,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 PLYRYAHDNXANEG-QMWPFBOUSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
- GFYLSDSUCHVORB-IOSLPCCCSA-N 1-methyladenosine Chemical compound C1=NC=2C(=N)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O GFYLSDSUCHVORB-IOSLPCCCSA-N 0.000 description 1
- WRKSCDGOQXKDME-UHFFFAOYSA-N 1-methylisoguanosine Natural products CN1C(=O)Nc2c(ncn2C3OC(CO)C(O)C3O)C1=N WRKSCDGOQXKDME-UHFFFAOYSA-N 0.000 description 1
- YEDFEBOUHSBQBT-UHFFFAOYSA-N 2,3-dihydroflavon-3-ol Chemical class O1C2=CC=CC=C2C(=O)C(O)C1C1=CC=CC=C1 YEDFEBOUHSBQBT-UHFFFAOYSA-N 0.000 description 1
- ZSZRUEAFVQITHH-UHFFFAOYSA-N 2-(2-methylprop-2-enoyloxy)ethyl 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CC(=C)C(=O)OCCOP([O-])(=O)OCC[N+](C)(C)C ZSZRUEAFVQITHH-UHFFFAOYSA-N 0.000 description 1
- SCNILGOVBBRMBK-SDBHATRESA-N 2-Phenylaminoadenosine Chemical compound N=1C=2N([C@H]3[C@@H]([C@H](O)[C@@H](CO)O3)O)C=NC=2C(N)=NC=1NC1=CC=CC=C1 SCNILGOVBBRMBK-SDBHATRESA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- UPJKSWLLCONYMW-UHFFFAOYSA-N 5'-Adenosine monophosphate Natural products COc1cc(O)c(C(=O)C)c(OC2OC(COC3OC(C)C(O)C(O)C3O)C(O)C(O)C2O)c1 UPJKSWLLCONYMW-UHFFFAOYSA-N 0.000 description 1
- NGSRMSVXLUMDAX-KQYNXXCUSA-N 6-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1-methylpurin-2-one Chemical compound C12=NC(=O)N(C)C(N)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NGSRMSVXLUMDAX-KQYNXXCUSA-N 0.000 description 1
- UIJIQXGRFSPYQW-UHFFFAOYSA-N 6-methylthiopurine Chemical compound CSC1=NC=NC2=C1N=CN2 UIJIQXGRFSPYQW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 102000007471 Adenosine A2A receptor Human genes 0.000 description 1
- 108010085277 Adenosine A2A receptor Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- IRDQNLLVRXMERV-UHFFFAOYSA-N CCCC[Na] Chemical compound CCCC[Na] IRDQNLLVRXMERV-UHFFFAOYSA-N 0.000 description 1
- PAOANWZGLPPROA-RQXXJAGISA-N CGS-21680 Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC(NCCC=3C=CC(CCC(O)=O)=CC=3)=NC(N)=C2N=C1 PAOANWZGLPPROA-RQXXJAGISA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- NGSRMSVXLUMDAX-UHFFFAOYSA-N Doridosine Natural products C12=NC(=O)N(C)C(N)=C2N=CN1C1OC(CO)C(O)C1O NGSRMSVXLUMDAX-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- RYECOJGRJDOGPP-UHFFFAOYSA-N Ethylurea Chemical compound CCNC(N)=O RYECOJGRJDOGPP-UHFFFAOYSA-N 0.000 description 1
- CITFYDYEWQIEPX-UHFFFAOYSA-N Flavanol Natural products O1C2=CC(OCC=C(C)C)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C=C1 CITFYDYEWQIEPX-UHFFFAOYSA-N 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- VQAYFKKCNSOZKM-IOSLPCCCSA-N N(6)-methyladenosine Chemical compound C1=NC=2C(NC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VQAYFKKCNSOZKM-IOSLPCCCSA-N 0.000 description 1
- OHLUUHNLEMFGTQ-UHFFFAOYSA-N N-methylacetamide Chemical compound CNC(C)=O OHLUUHNLEMFGTQ-UHFFFAOYSA-N 0.000 description 1
- VQAYFKKCNSOZKM-UHFFFAOYSA-N NSC 29409 Natural products C1=NC=2C(NC)=NC=NC=2N1C1OC(CO)C(O)C1O VQAYFKKCNSOZKM-UHFFFAOYSA-N 0.000 description 1
- 229930192627 Naphthoquinone Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000047703 Nonion Species 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 208000013200 Stress disease Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 150000003835 adenosine derivatives Chemical class 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229930015036 aurone Natural products 0.000 description 1
- 150000001530 aurones Chemical class 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- LUFPJJNWMYZRQE-UHFFFAOYSA-N benzylsulfanylmethylbenzene Chemical compound C=1C=CC=CC=1CSCC1=CC=CC=C1 LUFPJJNWMYZRQE-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- CNWSQCLBDWYLAN-UHFFFAOYSA-N butylurea Chemical compound CCCCNC(N)=O CNWSQCLBDWYLAN-UHFFFAOYSA-N 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 235000005513 chalcones Nutrition 0.000 description 1
- 150000001789 chalcones Chemical class 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- ALSTYHKOOCGGFT-UHFFFAOYSA-N cis-oleyl alcohol Natural products CCCCCCCCC=CCCCCCCCCO ALSTYHKOOCGGFT-UHFFFAOYSA-N 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001877 deodorizing effect Effects 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- RNPXCFINMKSQPQ-UHFFFAOYSA-N dicetyl hydrogen phosphate Chemical compound CCCCCCCCCCCCCCCCOP(O)(=O)OCCCCCCCCCCCCCCCC RNPXCFINMKSQPQ-UHFFFAOYSA-N 0.000 description 1
- 229940093541 dicetylphosphate Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- MWEQTWJABOLLOS-UHFFFAOYSA-L disodium;[[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-oxidophosphoryl] hydrogen phosphate;trihydrate Chemical compound O.O.O.[Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP([O-])(=O)OP(O)([O-])=O)C(O)C1O MWEQTWJABOLLOS-UHFFFAOYSA-L 0.000 description 1
- XWPWZOJBTOJEGW-UHFFFAOYSA-L disodium;benzene-1,3-disulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C1=CC=CC(S([O-])(=O)=O)=C1 XWPWZOJBTOJEGW-UHFFFAOYSA-L 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000008921 facial expression Effects 0.000 description 1
- 210000001097 facial muscle Anatomy 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 150000002206 flavan-3-ols Chemical class 0.000 description 1
- 235000011987 flavanols Nutrition 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 150000002208 flavanones Chemical class 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- NWKFECICNXDNOQ-UHFFFAOYSA-N flavylium Chemical compound C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=[O+]1 NWKFECICNXDNOQ-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical class COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229940095066 hydroxytyrosol Drugs 0.000 description 1
- 235000003248 hydroxytyrosol Nutrition 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229930013032 isoflavonoid Natural products 0.000 description 1
- 150000003817 isoflavonoid derivatives Chemical class 0.000 description 1
- 235000012891 isoflavonoids Nutrition 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229960003639 laurocapram Drugs 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 230000008376 long-term health Effects 0.000 description 1
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
- 229960001571 loperamide Drugs 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 229950004191 metrifudil Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- ACOHAEBNFWGQCL-UHFFFAOYSA-N n-(pyridin-2-ylmethyl)acetamide Chemical compound CC(=O)NCC1=CC=CC=N1 ACOHAEBNFWGQCL-UHFFFAOYSA-N 0.000 description 1
- SWINCIBSAYTBMF-UHFFFAOYSA-N n-(pyridin-2-ylmethyl)pyridine-3-carboxamide Chemical compound C=1C=CN=CC=1C(=O)NCC1=CC=CC=N1 SWINCIBSAYTBMF-UHFFFAOYSA-N 0.000 description 1
- RDBFCZVVOXVKLH-UHFFFAOYSA-N n-prop-2-enylpyridine-3-carboxamide Chemical compound C=CCNC(=O)C1=CC=CN=C1 RDBFCZVVOXVKLH-UHFFFAOYSA-N 0.000 description 1
- SQMWSBKSHWARHU-SDBHATRESA-N n6-cyclopentyladenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NC3CCCC3)=C2N=C1 SQMWSBKSHWARHU-SDBHATRESA-N 0.000 description 1
- 239000002159 nanocrystal Substances 0.000 description 1
- 150000002791 naphthoquinones Chemical class 0.000 description 1
- MRWXACSTFXYYMV-FDDDBJFASA-N nebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-FDDDBJFASA-N 0.000 description 1
- 229930014802 neoflavonoid Natural products 0.000 description 1
- 150000002804 neoflavonoids Chemical class 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- NCYVXEGFNDZQCU-UHFFFAOYSA-N nikethamide Chemical compound CCN(CC)C(=O)C1=CC=CN=C1 NCYVXEGFNDZQCU-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229930015704 phenylpropanoid Natural products 0.000 description 1
- 125000001474 phenylpropanoid group Chemical group 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- OHOPKHNWLCMLSW-UHFFFAOYSA-N pinoresinol Natural products C1=C(O)C(OC)=CC(C2C3C(C(OC3)C=3C=C(CO)C(O)=CC=3)CO2)=C1 OHOPKHNWLCMLSW-UHFFFAOYSA-N 0.000 description 1
- 235000007221 pinoresinol Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000002212 purine nucleoside Substances 0.000 description 1
- 239000003379 purinergic P1 receptor agonist Substances 0.000 description 1
- HDOUGSFASVGDCS-UHFFFAOYSA-N pyridin-3-ylmethanamine Chemical compound NCC1=CC=CN=C1 HDOUGSFASVGDCS-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 229960003581 pyridoxal Drugs 0.000 description 1
- 235000008164 pyridoxal Nutrition 0.000 description 1
- 239000011674 pyridoxal Substances 0.000 description 1
- 229940079877 pyrogallol Drugs 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 102000035025 signaling receptors Human genes 0.000 description 1
- 108091005475 signaling receptors Proteins 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 229940077386 sodium benzenesulfonate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940079842 sodium cumenesulfonate Drugs 0.000 description 1
- 229940048842 sodium xylenesulfonate Drugs 0.000 description 1
- VTGPMVCGAVZLQI-UHFFFAOYSA-M sodium;2-[4-(2-methylpropyl)phenyl]propanoate;dihydrate Chemical compound O.O.[Na+].CC(C)CC1=CC=C(C(C)C([O-])=O)C=C1 VTGPMVCGAVZLQI-UHFFFAOYSA-M 0.000 description 1
- KVCGISUBCHHTDD-UHFFFAOYSA-M sodium;4-methylbenzenesulfonate Chemical compound [Na+].CC1=CC=C(S([O-])(=O)=O)C=C1 KVCGISUBCHHTDD-UHFFFAOYSA-M 0.000 description 1
- QEKATQBVVAZOAY-UHFFFAOYSA-M sodium;4-propan-2-ylbenzenesulfonate Chemical compound [Na+].CC(C)C1=CC=C(S([O-])(=O)=O)C=C1 QEKATQBVVAZOAY-UHFFFAOYSA-M 0.000 description 1
- MZSDGDXXBZSFTG-UHFFFAOYSA-M sodium;benzenesulfonate Chemical compound [Na+].[O-]S(=O)(=O)C1=CC=CC=C1 MZSDGDXXBZSFTG-UHFFFAOYSA-M 0.000 description 1
- PVXCGWNPDFFPOV-UHFFFAOYSA-M sodium;pyridine-4-carboxylate Chemical compound [Na+].[O-]C(=O)C1=CC=NC=C1 PVXCGWNPDFFPOV-UHFFFAOYSA-M 0.000 description 1
- 150000003436 stilbenoids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 235000014101 wine Nutrition 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- BURBOJZOZGMMQF-UHFFFAOYSA-N xanthoxylol Natural products C1=C(O)C(OC)=CC=C1C1C(COC2C=3C=C4OCOC4=CC=3)C2CO1 BURBOJZOZGMMQF-UHFFFAOYSA-N 0.000 description 1
- 210000000216 zygoma Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Molecular Biology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
フリーラジカルの形成は、広く受け入れられている極めて重要な、皮膚の老化を引き起こすメカニズムである。フリーラジカルは、不対電子を持つ非常に反応性に富む分子であり、種々の細胞膜、脂質、タンパク質、RNA及びDNAに直接的にダメージを与えることがある。これらの活性酸素種のダメージの影響は、正常代謝中に内部的に、及び、種々の酸化ストレスを通じて外部的に誘発される。UV照射及び環境汚染は、皮膚でフリーラジカルを生じさせることにより、皮膚の老化を早めることがある。酸化防止剤は、フリーラジカルを除去すること及び続く酸化反応を阻害することにより酸化ストレスのダメージから細胞を保護する。酸化防止剤の局所適用は、皮膚の老化を予防するためのスキンケア商品に広く使用されている。
アデノシンは、多くの生理学的プロセスを調節する内因性プリンヌクレオシドである。ストレス又は傷害に関して、アデノシンは主に、低酸素症、虚血及び発作等の疾患における組織損傷を予防する細胞保護作用を提供することが知られている(Sebastiao AM, Ribeiro JA(2009), 「Adenosine receptors and the central nervous system」, Handb Exp Pharmacol. 193:471-534)。アデノシンはまた、細胞シグナル伝達受容体、A2Aの一つでの抗炎症薬であると考えられている(Trevethick MA, Mantell SJ, Stuart EF, Barnard A, Wright KN, Yeadon M(October 2008), 「Treating lung inflammation with agonists of the Adenosine A2A receptor: promises, problems and potential solutions」. Br. J. Pharmacol. 155(4)463-74))。創傷部位におけるアデノシンでの局所療法は、組織修復及び再構成を著しく増大し得る(Hasko G, Linden J, Cronstein B, Pacher P(September 2008). 「Adenosine receptors: therapeutic aspects for inflammatory and immune diseases」. Nat Rev Drug Discov 7(9): 759-70; Nakav S, Chaimovitz C, Sufaro Y(2008). Bozza, Patricia, ed. 「Anti-Inflammatory Preconditioning by Agonists of Adenosine Al Receptor」. PLoS ONE 3(5): e2107)。
化粧品市場は、老化及び皮膚のダメージの影響を抑制するのを助けるために、多くの活性成分を製剤に含み始めた。不幸なことに、幾つかのこれらの分子の有効性は、皮膚膜の天然バリアの特性により減少させられる。特に、最も外側の角質層は、親水性であるか、高親油性であるか、高分子量であるか又は荷電された化合物の低い皮膚浸透性を示す。
本発明の一態様は、(a)少なくとも一種のフェノール化合物及び(b)前記少なくとも一種のフェノール化合物を水に可溶化する十分量で、少なくとも一種のヒドロトロープを含む水性組成物を提供する。ヒドロトロープは、ニコチンアミド、カフェイン、PCAナトリウム、サリチル酸ナトリウム、尿素又はヒドロキシエチル尿素等の美容的に許容されるヒドロトロープであり得る。フェノール化合物は、フェノール又はポリフェノールのあらゆるタイプであり得る。
本発明の一態様は、(a)アデノシン及びアデノシン類似体からなる群より選択される少なくとも一種の化合物、及び(b)前記少なくとも一種の化合物(a)を水に可溶化する十分量で、少なくとも一種のヒドロトロープを含む水性組成物を提供する。成分(a)の化合物は、アデノシン、アデノシン類似体、又はアデノシン類似体若しくはアデノシンとアデノシン類似体とのあらゆる組み合わせであり得る。ヒドロトロープは、ニコチンアミド、カフェイン、PCAナトリウム、サリチル酸ナトリウム、尿素又はヒドロキシエチル尿素等の美容的に許容されるヒドロトロープであり得る。
本発明の一態様は、a)少なくとも一種のヒドロトロープ及びb)少なくとも一種の活性化合物を含む水性組成物であって、少なくとも一種のヒドロトロープが該活性化合物の経皮浸透を増加させる有効量で存在する水性組成物を提供する。好ましくは、ヒドロトロープは、ニコチンアミド、カフェイン、PCAナトリウム又はサリチル酸ナトリウム等の美容的に許容されるヒドロトロープである。活性化合物は、水溶性が低い可能性があり、ヒドロトロープ自体(若しくはヒドロトロープの組み合わせ)、又は容易に溶解される親水性分子により可溶化される必要がある。したがって、本発明の水性組成物は、局所適用のための少なくとも一種の活性化合物又は活性分子のバイオアベイラビリティを高めるために有効である。
本発明は、少なくとも一種のヒドロトロープ及び少なくとも一種の活性化合物を含む水性化粧品組成物に関する。本発明の組成物において有用な活性化合物は、フェノール化合物(例えば、ポリフェノール)、アデノシン及びアデノシン類似体、並びに老化及び皮膚のダメージの影響を抑制するのを助けるのに有用なその他の化合物を含む。
ヒドロトロープ(又はヒドロトロープ剤)は、両親媒性分子構造及び水溶性が低い有機分子の水溶性を著しく高める能力により特徴づけられた水溶性化合物の多様な種類である。
本発明の一態様は、化粧用途及び他用途の、少なくとも一種のフェノール化合物及び少なくとも一種のヒドロトロープを含む水性組成物を提供する。美容的に許容されるヒドロトロープ等のヒドロトロープは、フェノール化合物の水溶性を改善する。ヒドロトロープは、水を含んでいる全ての化粧品処方において、局所適用又は注射、及び食品用途、例えば飲料のための、フェノール化合物、特にポリフェノールを製剤化するために使用され得る。
本発明の一態様は、化粧用途の、(a)アデノシン及びアデノシン類似体からなる群より選択される少なくとも一種の化合物、及び(b)前記少なくとも一種の化合物(a)を水に可溶化する十分量で、少なくとも一種のヒドロトロープを含む水性組成物を提供する。美容的に許容されるヒドロトロープ等のヒドロトロープは、アデノシン及び/又はアデノシン類似体の水溶性を改善する。ヒドロトロープは、水を含んでいる全ての化粧品処方において、局所適用、注射又は経口投与のためのアデノシン及び/又はアデノシン類似体を製剤化するために使用され得る。
本発明の一態様は、a)少なくとも一種のヒドロトロープ及びb)少なくとも一種の活性化合物を含む水性組成物であって、少なくとも一種のヒドロトロープが活性分子の経皮浸透を増加させる有効量で存在する水性組成物を提供する。本発明の本態様の活性化合物は、先に述べたフェノール化合物、アデノシン及びアデノシン類似体の多く(全てでない場合)、並びにその他の化合物又は分子を含む。
水性組成物は、化粧品分野において従来から使用され、本発明による組成物の特性には影響を及ぼさない、少なくとも一種の添加剤、例えば、増粘剤、香料、真珠光沢剤、保存料、日焼け防止剤、陰イオン若しくは非イオン若しくは陽イオンあるいは両性ポリマー、タンパク質、タンパク質加水分解物、例えば18−メチルエイコサン酸、ビタミン、パンテノール、シリコン、植物油、動物油、鉱物油又は合成油等の脂肪酸、ゲル化剤、酸化防止剤、溶媒、香料、フィルター、スクリーニング剤、臭気吸収剤及び着色料も含んでもよい。これらの添加剤は、組成物の総重量に関し、限定されないが、好ましくは又は有利には0から50重量%、5から40重量%又は30から50重量%の範囲に収まる割合で、本発明の組成物中に存在し得る。
中国の薬草オウゴンの成分であるバイカリンは、フラボノイドの一種であるフラボンである。バイカリンは、酸化ストレス疾病、炎症、アレルギー、がん、細菌感染等に対する強力な効果を示す強力な酸化防止剤である。しかしながら、その水溶性は、以下に示されるように特に低いpHで非常に低く(通常のpH〜4.5で<0.01%)、pH>5で分解が生じる。
カフェインの水溶性はおよそ2%であり、これはヒドロトロープ剤としてのその機能を限定した。ニコチンアミドと混合することにより、カフェインの溶解度は、5%以上に高められ得る。また、カフェインとニコチンアミドとの組み合わせは、それら自体の何れか一つよりも効率的である。水中5%ニコチンアミドと5%カフェインの組み合わせは、水中およそ1%バイカリンを可溶化し、これは、バイカリンの水溶性を100倍以上著しく増加させた。
このモデルシステムにおいて、脂質二重層は、検出可能な化合物を捕捉することができ、脂質疾患の場合(即ち、ヒドロトロープの存在中)、該化合物は構造から放出され、化学アッセイで測定され得る。
ヒト皮膚に対する浸透促進剤の効果を更に評価するため、出願人は、CARS(コヒーレント反ストークスラマン分光法)実験を行った。この技術を使用して、出願人は、ヒト生体外皮膚における酸化防止剤の浸透の深さを観察することができ、ヒドロトロープ非含有製剤、一のヒドロトロープを含む製剤、及びヒドロトロープの組み合わせを含む製剤間の変動性を比較することができる。
一又は複数のヒドロトロープ剤を水に完全に溶解させることによりヒドロトロープ溶液をある一定の濃度で調製した後、アデノシンを添加して撹拌子又はその他のミキサーを使用して混合し、すぐに可溶化が生じ、最高濃度が達成されるまで続けて、これを、その条件下のアデノシンの溶解度として定義した。溶解度を超えない濃度の、透明で安定した溶液は、>1時間撹拌した後、すぐに適用できる。アデノシンを溶解させるためのこの手順の後には加熱は必要ない。全て室温で調製される。
Claims (27)
- (a)フェノール化合物、アデノシン及びアデノシン類似体からなる群より選択される少なくとも一種の活性化合物;
(b)ニコチンアミド、カフェイン、PCAナトリウム及びサリチル酸ナトリウムからなる群より選択される少なくとも一種のヒドロトロープ;並びに
(c)水
を含む水性化粧品組成物であって、
前記ヒドロトロープが、前記少なくとも一種の活性化合物を可溶化する有効量で前記水中に存在する、水性化粧品組成物。 - 前記少なくとも一種の活性化合物がフェノール化合物を含む、請求項1に記載の組成物。
- 前記少なくとも一種の活性化合物がアデノシン又はアデノシン類似体の少なくとも一つを含む、請求項1に記載の組成物。
- 前記少なくとも一種の活性化合物が少なくとも一種のポリフェノールである、請求項1に記載の組成物。
- 前記少なくとも一種の活性化合物がフェノール化合物である、請求項1に記載の組成物。
- 前記少なくとも一種のヒドロトロープがカフェイン、PCAナトリウム及びサリチル酸ナトリウムからなる群より選択される、請求項1に記載の組成物。
- 前記少なくとも一種のヒドロトロープが(a)ニコチンアミド及びカフェイン、(b)カフェイン、(c)PCAナトリウム又は(d)サリチル酸ナトリウムである、請求項1に記載の組成物。
- 前記少なくとも一種のヒドロトロープがニコチンアミド及びカフェインである、請求項1に記載の組成物。
- 前記少なくとも一種のヒドロトロープが、組成物の総重量に基づき、約0.1%から約20%の量で前記組成物中に存在する、請求項1に記載の組成物。
- 前記活性化合物が、組成物の総重量に基づき、約0.01%から約20%の量で前記組成物中に存在する、請求項1に記載の組成物。
- 水性化粧品組成物を調製するための方法であって、フェノール化合物、アデノシン及びアデノシン類似体からなる群より選択される少なくとも一種の活性化合物;ニコチンアミド、カフェイン、PCAナトリウム及びサリチル酸ナトリウムからなる群より選択される少なくとも一種のヒドロトロープ;及び(c)水を前記組成物中に含ませることを含み、前記ヒドロトロープが前記活性化合物を可溶化する十分量で前記水中に存在する、方法。
- 皮膚に水性化粧品組成物を適用することを含む方法であって、(a)フェノール化合物、アデノシン及びアデノシン類似体からなる群より選択される少なくとも一種の活性化合物;(b)ニコチンアミド、カフェイン、PCAナトリウム及びサリチル酸ナトリウムからなる群より選択される少なくとも一種のヒドロトロープ;並びに(c)水を含み、前記ヒドロトロープが前記少なくとも一種の活性化合物を可溶化する有効量で前記水中に存在する、方法。
- 前記少なくとも一種の活性化合物がフェノール化合物である、請求項12に記載の方法。
- (a)フェノール化合物、アデノシン及びアデノシン類似体からなる群より選択される少なくとも一種の活性化合物;(b)ニコチンアミド、カフェイン、PCAナトリウム及びサリチル酸ナトリウムからなる群より選択される少なくとも一種のヒドロトロープ;並びに(c)水を含む水性化粧品組成物であって、前記ヒドロトロープが該活性化合物の経皮浸透を増加させる有効量で存在する、水性化粧品組成物。
- 前記少なくとも一種の活性化合物がフェノール化合物である、請求項14に記載の組成物。
- 前記少なくとも一種の活性化合物の水溶性が低い、請求項1に記載の水性組成物。
- 前記少なくとも一種のヒドロトロープがニコチンアミド及びカフェインである、請求項14に記載の組成物。
- 前記少なくとも一種のヒドロトロープが(a)ニコチンアミド及びカフェイン;(b)カフェイン;(c)PCAナトリウム;又は(d)サリチル酸ナトリウムである、請求項14に記載の組成物。
- 皮膚に水性組成物を適用することを含む、活性分子のバイオアベイラビリティを高めるための方法であって、前記組成物がa)フェノール化合物、アデノシン及びアデノシン類似体からなる群より選択される少なくとも一種の活性化合物;(b)ニコチンアミド、カフェイン、PCAナトリウム及びサリチル酸ナトリウムからなる群より選択される少なくとも一種のヒドロトロープ;並びに(c)水を含み、前記ヒドロトロープが該活性化合物の経皮浸透を増加させる有効量で存在する、方法。
- 水性組成物を調製する方法であって、(a)フェノール化合物、アデノシン及びアデノシン類似体からなる群より選択される少なくとも一種の活性化合物;(b)ニコチンアミド、カフェイン、PCAナトリウム及びサリチル酸ナトリウムからなる群より選択される少なくとも一種のヒドロトロープ;並びに(c)水を前記組成物中に含ませることを含み、前記ヒドロトロープが該活性化合物の経皮浸透を増加させる有効量で存在する、方法。
- 前記少なくとも一種の活性化合物がフェノール化合物である、請求項11に記載の方法。
- 前記少なくとも一種のヒドロトロープが(a)ニコチンアミド及びカフェイン;(b)カフェイン;(c)PCAナトリウム;又は(d)サリチル酸ナトリウムである、請求項11に記載の方法。
- 前記少なくとも一種のヒドロトロープが(a)ニコチンアミド及びカフェイン;(b)カフェイン;(c)PCAナトリウム;又は(d)サリチル酸ナトリウムである、請求項12に記載の方法。
- 前記少なくとも一種の活性化合物がフェノール化合物である、請求項20に記載の方法。
- 前記少なくとも一種のヒドロトロープが(a)ニコチンアミド及びカフェイン;(b)カフェイン;(c)PCAナトリウム;又は(d)サリチル酸ナトリウムである、請求項20に記載の方法。
- 前記少なくとも一種の活性化合物がフェノール化合物である、請求項21に記載の方法。
- 前記少なくとも一種のヒドロトロープが(a)ニコチンアミド及びカフェイン;(b)カフェイン;(c)PCAナトリウム;又は(d)サリチル酸ナトリウムである、請求項21に記載の方法。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/650,774 US9023826B2 (en) | 2012-10-12 | 2012-10-12 | Compositions containing adenosine and the hydrotropes caffeine and nicotinamide for cosmetic use |
US13/651,038 | 2012-10-12 | ||
US13/650,933 | 2012-10-12 | ||
US13/650,774 | 2012-10-12 | ||
US13/651,038 US9107853B2 (en) | 2012-10-12 | 2012-10-12 | Compositions containing phenolic compounds and hydrotropes for cosmetic use |
US13/650,933 US9018177B2 (en) | 2012-10-12 | 2012-10-12 | Cosmetic compositions for increasing bioavailability of the active compounds baicalin and/or vitamin C |
PCT/US2013/064466 WO2014059228A1 (en) | 2012-10-12 | 2013-10-11 | Cosmetic compositions containing at least one hydrotrope and at least one active compound |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015533170A true JP2015533170A (ja) | 2015-11-19 |
JP6295261B2 JP6295261B2 (ja) | 2018-03-14 |
Family
ID=50477909
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015536914A Active JP6295261B2 (ja) | 2012-10-12 | 2013-10-11 | 少なくとも一種のヒドロトロープ及び少なくとも一種の活性化合物を含む化粧品組成物 |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP2906547B2 (ja) |
JP (1) | JP6295261B2 (ja) |
KR (1) | KR102261301B1 (ja) |
CN (1) | CN104918927B (ja) |
ES (1) | ES2768323T5 (ja) |
WO (1) | WO2014059228A1 (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016523920A (ja) * | 2013-07-01 | 2016-08-12 | ロレアル | 二つのフェノール化合物を含有する化粧用途のための組成物 |
JP2019500381A (ja) * | 2015-12-29 | 2019-01-10 | ロレアル | 安定した抗酸化組成物 |
WO2019131975A1 (ja) * | 2017-12-27 | 2019-07-04 | 花王株式会社 | 難水溶性芳香族化合物含有組成物の製造方法 |
JP2020502186A (ja) * | 2016-12-21 | 2020-01-23 | ロレアル | バイカリン、キサンチン塩基、ビタミンb3及び多価金属カチオン塩を含有する油中水型エマルジョン |
JP2020505387A (ja) * | 2017-01-26 | 2020-02-20 | ロレアル | ポリダチンを含むマイクロエマルジョン及び使用方法 |
JP2020512381A (ja) * | 2017-03-31 | 2020-04-23 | アモーレパシフィック コーポレーションAmorepacific Corporation | アメントフラボンの安定度が向上された透明または半透明の化粧料組成物 |
JP6921284B1 (ja) * | 2020-09-01 | 2021-08-18 | 株式会社 資生堂 | アデノシン含有組成物、及びアデノシンの析出を抑制する方法 |
WO2022050034A1 (ja) * | 2020-09-01 | 2022-03-10 | 株式会社 資生堂 | アデノシン含有組成物、及びアデノシンの析出を抑制する方法 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3046077B1 (fr) * | 2015-12-23 | 2020-01-10 | L'oreal | Composition comprenant la baicaline a haute concentration |
JP2019536769A (ja) * | 2016-10-31 | 2019-12-19 | スダ リミテッド | 粘膜活性剤送達 |
US10898420B2 (en) * | 2016-10-31 | 2021-01-26 | L'oreal | Compositions containing phenolic compounds having synergistic antioxidant benefits |
KR102186610B1 (ko) * | 2018-12-27 | 2020-12-04 | 주식회사 마크로케어 | 소포리코사이드 가용화 방법 |
KR102294985B1 (ko) * | 2019-12-11 | 2021-08-30 | 코스맥스 주식회사 | 난용성 물질의 안정화용 화장료 조성물 |
KR102337124B1 (ko) * | 2021-05-13 | 2021-12-10 | (주)바이오제닉스 | 탈모 개선용 복합 파우더 및 이를 포함하는 모발용 화장료 조성물 |
KR102632256B1 (ko) * | 2021-05-28 | 2024-02-01 | 주식회사 나노진 | 난용성 방향족 화합물의 수용화 조성물 및 그의 제조방법 및 이로부터 제조된 화장료 조성물 |
KR102653555B1 (ko) * | 2023-08-02 | 2024-04-03 | 한국콜마주식회사 | 유효성분이 안정화된 조성물 |
CN117562829B (zh) * | 2024-01-15 | 2024-04-19 | 深圳市护家科技有限公司 | 促进熊果苷提亮功效的组合物及皮肤护理组合物 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6150918A (ja) * | 1984-08-20 | 1986-03-13 | Ichimaru Fuarukosu Kk | バイカリン又はバイカレイン含有化粧料用組成液 |
JP2002502384A (ja) * | 1997-05-28 | 2002-01-22 | アプライド・リサーチ・システムズ・エイアールエス・ホールディング・ナムローゼ・フェンノートシャップ | 生理学上の媒体中において低い溶解性を有するペプチドの薬剤組成物 |
WO2009123098A1 (ja) * | 2008-03-31 | 2009-10-08 | 杏林製薬株式会社 | ガチフロキサシン含有水性液剤、その製造方法、および、該水性液剤の低温保存および凍結融解時の沈殿生成を抑制する方法 |
JP2011504891A (ja) * | 2007-11-29 | 2011-02-17 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 溶解性を改良するためのα−アミノ酸誘導体 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4488989A (en) * | 1983-11-14 | 1984-12-18 | Lever Brothers Company | Aqueous compositions containing urea as a hydrotrope |
US5532012A (en) | 1995-06-02 | 1996-07-02 | Thomas J. Lipton Co., Division Of Conopco, Inc. | Process for preparation of purified tea components using preconcentration by cream separation and solubilization followed by medium pressure chromatography and/or preparative HPLC |
US6221823B1 (en) * | 1995-10-25 | 2001-04-24 | Reckitt Benckiser Inc. | Germicidal, acidic hard surface cleaning compositions |
US5900416A (en) | 1996-02-01 | 1999-05-04 | Anthea Enterprises Incorporated | Aqueous caffeine dosage forms |
US6319507B1 (en) | 1997-05-02 | 2001-11-20 | Kobo Products, Inc. | Agar gel bead composition and method |
EP1126812A4 (en) | 1998-10-26 | 2005-10-12 | Univ Massachusetts | TREATMENT OF THE SKIN WITH ADENOSINE OR AN ADENOSINE ANALOG |
US6355657B1 (en) | 1998-12-30 | 2002-03-12 | Atrix Laboratories, Inc. | System for percutaneous delivery of opioid analgesics |
AU5471000A (en) * | 1999-06-23 | 2001-01-09 | Dial Corporation, The | Antibacterial compositions |
US20030104080A1 (en) * | 1999-09-07 | 2003-06-05 | Singh Parashu Ram | Topical urea composition |
US20060147508A1 (en) | 2002-10-04 | 2006-07-06 | Bioderm Research | Concurrent Enhancement of Skin Penetration of Organic Base Active Agents and Organic Hydroxy Acid Active Agents as Their Ion-Pair Complexes |
US20040146474A1 (en) | 2002-11-26 | 2004-07-29 | L'oreal | Method for softening lines and relaxing the skin with adenosine and adenosine analogues |
US20050276762A1 (en) * | 2004-06-15 | 2005-12-15 | Tapas Das | Topical compositions containing 5'-adenosine-diphosphate ribose |
KR101162251B1 (ko) | 2004-09-14 | 2012-07-04 | 에스티 라우더 코디네이션 센터 엔.브이. | 포스포릴화된 폴리페놀류를 함유하는 국소용 조성물 |
EP1802278A4 (en) | 2004-10-22 | 2012-08-01 | Dynamis Therapeutics Inc | DERIVATIVE ADMINISTRATION OF N-METHYL-GLUCAMINE AND N-METHYL-GLUCAMINE COMPOUNDS |
EP1922067A1 (en) | 2005-08-11 | 2008-05-21 | Medical College Of Georgia Research Institute | Modified green tea polyphenol formulations |
US20070196296A1 (en) | 2005-12-13 | 2007-08-23 | Rosemarie Osborne | Personal care compositions |
US20070232561A1 (en) | 2006-03-31 | 2007-10-04 | Edward Leung | Pharmaceutical compositions for promoting wound healing |
EP1867729A1 (en) | 2006-06-14 | 2007-12-19 | Libragen | Water soluble phenolics derivatives with dermocosmetic and therapeutic applications |
EP2099420B8 (en) | 2006-11-17 | 2017-03-15 | PharmaSol GmbH | Nanocrystals for use in topical cosmetic formulations and method of production thereof |
US20080219927A1 (en) | 2007-01-18 | 2008-09-11 | Thakur Ajit B | Adenosine derivative formulations for medical imaging |
CN101238886A (zh) * | 2008-01-31 | 2008-08-13 | 王科大 | 红景天甙抗疲劳饮料 |
EP2276463A4 (en) | 2008-04-11 | 2013-12-04 | Univ Louisiana State | GLYCOSIDES OF DITERPENE AS NATURAL SOLUBILISANTS |
WO2009140588A1 (en) | 2008-05-15 | 2009-11-19 | Trustees Of Tufts College | Silk polymer-based adenosine release: therapeutic potential for epilepsy |
EP2642973B1 (en) * | 2010-11-22 | 2018-03-21 | DSM IP Assets B.V. | Cosmetic composition for skin whitening comprising resveratrol |
CA2816631C (en) * | 2010-12-21 | 2015-12-01 | The Procter & Gamble Company | Hair care compositions and methods to improve hair appearance |
KR20130109282A (ko) * | 2012-03-27 | 2013-10-08 | 주식회사 스킨앤테크 | 수용성 카페인 및 그 제조방법 |
US9072919B2 (en) * | 2012-10-12 | 2015-07-07 | L'oreal S.A. | Synergistic antioxidant cosmetic compositions containing at least one of baicalin and taxifolin, at least one of caffeine and nicotinamide, at least one of vitamin C and resveratrol and ferulic acid |
-
2013
- 2013-10-11 ES ES13844959T patent/ES2768323T5/es active Active
- 2013-10-11 EP EP13844959.0A patent/EP2906547B2/en active Active
- 2013-10-11 JP JP2015536914A patent/JP6295261B2/ja active Active
- 2013-10-11 WO PCT/US2013/064466 patent/WO2014059228A1/en active Application Filing
- 2013-10-11 KR KR1020157012276A patent/KR102261301B1/ko active IP Right Grant
- 2013-10-11 CN CN201380065134.5A patent/CN104918927B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6150918A (ja) * | 1984-08-20 | 1986-03-13 | Ichimaru Fuarukosu Kk | バイカリン又はバイカレイン含有化粧料用組成液 |
JP2002502384A (ja) * | 1997-05-28 | 2002-01-22 | アプライド・リサーチ・システムズ・エイアールエス・ホールディング・ナムローゼ・フェンノートシャップ | 生理学上の媒体中において低い溶解性を有するペプチドの薬剤組成物 |
JP2011504891A (ja) * | 2007-11-29 | 2011-02-17 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 溶解性を改良するためのα−アミノ酸誘導体 |
WO2009123098A1 (ja) * | 2008-03-31 | 2009-10-08 | 杏林製薬株式会社 | ガチフロキサシン含有水性液剤、その製造方法、および、該水性液剤の低温保存および凍結融解時の沈殿生成を抑制する方法 |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016523920A (ja) * | 2013-07-01 | 2016-08-12 | ロレアル | 二つのフェノール化合物を含有する化粧用途のための組成物 |
JP2019500381A (ja) * | 2015-12-29 | 2019-01-10 | ロレアル | 安定した抗酸化組成物 |
JP2020502186A (ja) * | 2016-12-21 | 2020-01-23 | ロレアル | バイカリン、キサンチン塩基、ビタミンb3及び多価金属カチオン塩を含有する油中水型エマルジョン |
JP2020505387A (ja) * | 2017-01-26 | 2020-02-20 | ロレアル | ポリダチンを含むマイクロエマルジョン及び使用方法 |
JP7080247B2 (ja) | 2017-03-31 | 2022-06-03 | アモーレパシフィック コーポレーション | アメントフラボンの安定度が向上した透明または半透明の化粧料組成物 |
JP2020512381A (ja) * | 2017-03-31 | 2020-04-23 | アモーレパシフィック コーポレーションAmorepacific Corporation | アメントフラボンの安定度が向上された透明または半透明の化粧料組成物 |
JP2019119740A (ja) * | 2017-12-27 | 2019-07-22 | 花王株式会社 | 難水溶性芳香族化合物含有組成物の製造方法 |
CN111491604A (zh) * | 2017-12-27 | 2020-08-04 | 花王株式会社 | 含有水难溶性芳香族化合物的组合物的制造方法 |
EP3733155A4 (en) * | 2017-12-27 | 2021-03-10 | Kao Corporation | PROCESS FOR MANUFACTURING A COMPOSITION WHICH INCLUDES AN AROMATIC COMPOUND LOW WATER SOLUBLE |
WO2019131975A1 (ja) * | 2017-12-27 | 2019-07-04 | 花王株式会社 | 難水溶性芳香族化合物含有組成物の製造方法 |
EP4032524A1 (en) * | 2017-12-27 | 2022-07-27 | Kao Corporation | Method for producing composition containing hardly water-soluble aromatic compound |
US11419797B2 (en) | 2017-12-27 | 2022-08-23 | Kao Corporation | Method for producing composition containing hardly water-soluble aromatic compound |
CN111491604B (zh) * | 2017-12-27 | 2023-03-21 | 花王株式会社 | 含有水难溶性芳香族化合物的组合物的制造方法 |
JP7340929B2 (ja) | 2017-12-27 | 2023-09-08 | 花王株式会社 | 難水溶性芳香族化合物含有組成物の製造方法 |
JP6921284B1 (ja) * | 2020-09-01 | 2021-08-18 | 株式会社 資生堂 | アデノシン含有組成物、及びアデノシンの析出を抑制する方法 |
WO2022050034A1 (ja) * | 2020-09-01 | 2022-03-10 | 株式会社 資生堂 | アデノシン含有組成物、及びアデノシンの析出を抑制する方法 |
JP2022041622A (ja) * | 2020-09-01 | 2022-03-11 | 株式会社 資生堂 | アデノシン含有組成物、及びアデノシンの析出を抑制する方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2014059228A1 (en) | 2014-04-17 |
KR20150092102A (ko) | 2015-08-12 |
ES2768323T5 (es) | 2023-03-08 |
EP2906547A4 (en) | 2016-03-16 |
WO2014059228A4 (en) | 2014-06-19 |
KR102261301B1 (ko) | 2021-06-07 |
EP2906547B1 (en) | 2019-11-20 |
EP2906547B2 (en) | 2022-10-26 |
CN104918927B (zh) | 2018-09-07 |
ES2768323T3 (es) | 2020-06-22 |
EP2906547A1 (en) | 2015-08-19 |
CN104918927A (zh) | 2015-09-16 |
JP6295261B2 (ja) | 2018-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6295261B2 (ja) | 少なくとも一種のヒドロトロープ及び少なくとも一種の活性化合物を含む化粧品組成物 | |
KR101734424B1 (ko) | 난용성 화합물의 용해도를 증가시키는 방법과 이와 같은 화합물의 제형을 제조하는 방법 및 사용하는 방법 | |
JP6257703B2 (ja) | フラボノイド含有組成物の製造方法及び使用 | |
ES2759104T3 (es) | Composiciones que contienen dos compuestos fenólicos para uso cosmético | |
KR101817635B1 (ko) | 난용성 화합물의 용해도를 증가시키는 방법과 이와 같은 화합물의 제형을 제조하는 방법 및 사용하는 방법 | |
JP6352560B2 (ja) | アスコルビン酸及び/又はその塩を含有する外用組成物 | |
EP3117821B1 (en) | Method for producing ceramide dispersion composition | |
US9018177B2 (en) | Cosmetic compositions for increasing bioavailability of the active compounds baicalin and/or vitamin C | |
US9023826B2 (en) | Compositions containing adenosine and the hydrotropes caffeine and nicotinamide for cosmetic use | |
KR20200043406A (ko) | 미백제, 미백용 피부 외용제 및 피부의 미백 방법 | |
CN107613945B (zh) | 染料木素甲醚-含有纳米脂质体及其制备方法以及包含其的化妆品组合物 | |
JP2021042241A (ja) | 外用組成物 | |
EP2952194B1 (en) | Emulsion composition | |
JP2006290873A (ja) | アクアポリン発現促進剤 | |
JP6356457B2 (ja) | セラミド配合外用剤組成物 | |
JP2011241164A5 (ja) | ||
JP2004323480A (ja) | 育毛養毛剤 | |
JP2005206536A (ja) | 育毛剤組成物 | |
JP5856761B2 (ja) | 皮膚外用剤およびその製造方法 | |
JP2000229811A (ja) | 皮膚外用剤 | |
JP2023505368A (ja) | ケラチン物質を明色化及び/又は白色化するための組成物 | |
EP2745835A1 (de) | Neuartige Vesikel für die topische Anwendung in der Pharmazie und Kosmetik | |
Suksawad | Preparation of Nicotinamide Microemulsions and Formulation Development for Cosmetic Application | |
JP2014037448A (ja) | エージング対応用の皮膚外用剤の製造方法 | |
JP2001270824A (ja) | 経皮吸収促進性皮膚外用剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160927 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160927 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170714 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170725 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171024 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180130 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180219 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6295261 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |